Orphazyme has appointed Andrew Mercieca as observer and consultant to the board, intending to formally appoint him member at the company's annual general meeting in April, it reports in a press release.
The vacancy was left by Board Member at Orphazyme Catherine Moukheibir, who announced her decision to step down from her position on Thursday.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.